We invite you to join a team bringing hope to 100+ million OA sufferers throughout the world.
We look forward to reviewing your resume. Please contact us via LinkedIn.
Our Company
Better Treatments for OA
Moebius Medical is a clinical-stage biotech company developing novel treatments for osteoarthritis (OA). Our lead product, MM-II, is an intra-articular injection for treating pain in knee OA. MM-II demonstrated safety and efficacy in a Phase IIb clinical trial, and will begin Phase III clinical development shortly.
Leveraging innovative IP regarding a novel use of liposomal technology, Moebius Medical was established in 2008 within the RAD Biomed Accelerator.
Moebius’s core IP was developed by Prof. Yechezkel Barenholz and Prof. Izhak Etsion, and was licensed to Moebius from Yissum, the Hebrew University Technology Transfer Company; T3, the Technology Transfer arm of the Technion Institute; and by Hadasit, the Technology Transfer company of Hadassah Medical Center.
In 2016, Moebius entered a joint collaboration and license agreement with Sun Pharmaceuticals Industries Ltd. to jointly develop MM-II for treating of OA in humans.
Contact
